ALTEOGEN Inc.

A196170

KR7196170005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-29 pm EDT			5-day change	1st Jan Change
180,000 ^KRW	-1.15%		-3.17%	+82.74%

2023	Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA	CI
2023	ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

ALTEOGEN Inc. authorizes a Buyback Plan.

December 11, 2016

The Board of Directors of ALTEOGEN Inc. has authorized a buyback plan on December 12, 2016.

Latest news about ALTEOGEN Inc.

Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA	23-09-05	CI
ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
ALTEOGEN Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
ALTEOGEN Inc. Enters into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by its Hybrozyme Technology	23-01-02	CI
Alteogen Inc. Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients	21-03-08	CI
Alteogen Enters Into Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled by Its Hybrozyme™ Technology	21-01-07	CI
ALTEOGEN Inc. announced that it has received KRW 74.999925 billion in funding from SG Core Co., Ltd.	21-01-06	CI
ALTEOGEN Inc. announced that it expects to receive KRW 74.999925 billion in funding from SG Core Co., Ltd.	20-12-13	CI
ALTEOGEN Inc. announced that it has received KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation	20-11-11	CI
ALTEOGEN Inc. announced that it expects to receive KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation	20-11-03	CI
ALTEOGEN Inc.(KOSDAQ:A196170) added to FTSE All-World Index	20-09-21	CI
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme Technology to Enable Subcutaneous Administration of Biologic Products	20-06-24	CI
ALTEOGEN Inc. Presents the First-In-Human Data on Alt-P7, A Her2-Targeting Antibody-Drug Conjugate At ASCO 2020	20-05-29	CI
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of its Hybrozyme™ Technology to Enable Subcutaneous Administration of Biologic Products	19-12-02	CI
Alteogen Inc. Signs Licensing Agreement with Cristalia Produtos Quimicos Farmaceuticos Ltda	19-07-22	CI
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH	18-12-03	CI
ALTEOGEN Inc. announced that it has received KRW 31.999718 billion in funding from KB Securities Co.,Ltd, Shinhan Investment Corp., Meritz Securities Co., Ltd., Korea Investment Holdings Co., Ltd., Kiwoom Securities Co., Ltd.	18-04-18	CI
ALTEOGEN Inc. announced that it expects to receive KRW 31.999718 billion in funding from KB Securities Co.,Ltd, Shinhan Investment Corp., Meritz Securities Co., Ltd., Korea Investment Holdings Co., Ltd., Kiwoom Securities Co., Ltd.	18-04-11	CI
Tranche Update on ALTEOGEN Inc.'s Equity Buyback Plan announced on December 12, 2016.	17-06-12	CI
ALTEOGEN Inc.’s Equity Buyback announced on December 12, 2016 has expired.	17-06-11	CI
Qilu Pharmaceutical Co Ltd Enters into License Agreement with Alteogen Inc	17-04-02	CI
Tranche Update on ALTEOGEN Inc.'s Equity Buyback Plan announced on December 12, 2016.	17-03-14	CI
ALTEOGEN Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	16-12-11	CI
ALTEOGEN Inc. authorizes a Buyback Plan.	16-12-11	CI
3SBio Inc. Enters into an Exclusive Licensing Deal with Alteogen Inc	15-10-11	CI

Alteogen Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company operates biobetter business segment, which develops protein pharmaceuticals and cancer therapies, and bio similar business segment, which develops bio similar and animal medicines. The Company mainly provides growth hormone, herceptin, humira, antibodies, animal drugs and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ALTEOGEN Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

180,000 KRW

Average target price

201,250 KRW

Spread / Average Target

+11.81%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ALTEOGEN INC.	+82.74%	7.07B
CSL LIMITED	-2.27%	89.01B
SAMSUNG BIOLOGICS CO.,LTD.	-3.68%	37.79B
BIOGEN INC.	-14.91%	31.22B
UCB	+60.33%	26.1B
BIOMARIN PHARMACEUTICAL INC.	-22.72%	14.25B
INCYTE CORPORATION	-8.73%	12.8B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.57%	11.65B
SWEDISH ORPHAN BIOVITRUM AB	+4.04%	8.7B
INNOVENT BIOLOGICS, INC.	-17.31%	7.45B

Biopharmaceuticals

ALTEOGEN Inc.

Equities

A196170

KR7196170005

Pharmaceuticals

ALTEOGEN Inc. authorizes a Buyback Plan.

Latest news about ALTEOGEN Inc.

Chart ALTEOGEN Inc.

Company Profile

Income Statement Evolution

Ratings for ALTEOGEN Inc.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals